DnB Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.7M | Buy |
49,314
+5,933
| +14% | +$4.04M | 0.09% | 162 |
|
|
2026
Q1 | $33.5M | Sell |
43,381
-2,776
| -6% | -$2.13M | 0.12% | 133 |
|
|
2025
Q4 | $35.6M | Sell |
46,157
-1,114
| -2% | -$757K | 0.12% | 113 |
|
|
2025
Q3 | $26.6M | Buy |
47,271
+616
| +1% | +$348K | 0.1% | 154 |
|
|
2025
Q2 | $24.5M | Sell |
46,655
-3,472
| -7% | -$1.94M | 0.1% | 151 |
|
|
2025
Q1 | $31.8M | Buy |
50,127
+14,323
| +40% | +$9.85M | 0.15% | 115 |
|
|
2024
Q4 | $25.5M | Buy |
35,804
+2,685
| +8% | +$2.25M | 0.11% | 145 |
|
|
2024
Q3 | $34.8M | Buy |
33,119
+689
| +2% | +$767K | 0.16% | 112 |
|
|
2024
Q2 | $34.1M | Buy |
32,430
+1,196
| +4% | +$1.16M | 0.16% | 104 |
|
|
2024
Q1 | $30.1M | Sell |
31,234
-1,059
| -3% | -$1.01M | 0.16% | 109 |
|
|
2023
Q4 | $28.4M | Buy |
32,293
+1,532
| +5% | +$1.26M | 0.15% | 119 |
|
|
2023
Q3 | $25.3M | Buy |
30,761
+1,482
| +5% | +$1.16M | 0.15% | 117 |
|
|
2023
Q2 | $21M | Buy |
29,279
+7,492
| +34% | +$5.78M | 0.12% | 138 |
|
|
2023
Q1 | $17.9M | Buy |
21,787
+1,255
| +6% | +$947K | 0.11% | 149 |
|
|
2022
Q4 | $14.8M | Sell |
20,532
-211
| -1% | -$156K | 0.1% | 169 |
|
|
2022
Q3 | $14.3M | Sell |
20,743
-10,140
| -33% | -$6.38M | 0.11% | 165 |
|
|
2022
Q2 | $18.3M | Sell |
30,883
-1,666
| -5% | -$1.08M | 0.13% | 144 |
|
|
2022
Q1 | $22.7M | Sell |
32,549
-1,270
| -4% | -$803K | 0.14% | 136 |
|
|
2021
Q4 | $21.4M | Sell |
33,819
-6,429
| -16% | -$3.95M | 0.13% | 147 |
|
|
2021
Q3 | $24.4M | Sell |
40,248
-7,043
| -15% | -$4.37M | 0.16% | 122 |
|
|
2021
Q2 | $26.4M | Buy |
47,291
+5,195
| +12% | +$2.63M | 0.18% | 111 |
|
|
2021
Q1 | $19.9M | Buy |
42,096
+4,992
| +13% | +$2.43M | 0.15% | 122 |
|
|
2020
Q4 | $17.9M | Buy |
37,104
+795
| +2% | +$429K | 0.16% | 122 |
|
|
2020
Q3 | $20.3M | Sell |
36,309
-41,284
| -53% | -$25M | 0.22% | 86 |
|
|
2020
Q2 | $48.4M | Buy |
77,593
+11,248
| +17% | +$6.38M | 0.57% | 36 |
|
|
2020
Q1 | $32.4M | Buy |
66,345
+4,436
| +7% | +$1.83M | 0.48% | 40 |
|
|
2019
Q4 | $23.2M | Buy |
61,909
+11,339
| +22% | +$3.81M | 0.23% | 80 |
|
|
2019
Q3 | $14M | Buy |
50,570
+18,751
| +59% | +$5.55M | 0.16% | 111 |
|
|
2019
Q2 | $9.96M | Sell |
31,819
-17,580
| -36% | -$5.85M | 0.11% | 141 |
|
|
2019
Q1 | $20.3M | Sell |
49,399
-4,099
| -8% | -$1.69M | 0.23% | 80 |
|
|
2018
Q4 | $20M | Buy |
53,498
+30,868
| +136% | +$11.3M | 0.26% | 79 |
|
|
2018
Q3 | $9.14M | Buy |
+22,630
| New | +$8.61M | 0.1% | 144 |
|
|
2018
Q2 | – | Sell |
-26,400
| Closed | -$9.09M | – | 637 |
|
|
2018
Q1 | $9.09M | Buy |
26,400
+2,100
| +9% | +$730K | 0.11% | 141 |
|
|
2017
Q4 | $9.14M | Buy |
+24,300
| New | +$9.84M | 0.11% | 137 |
|
Other funds holding REGN
DnB Asset Management's REGN Position: Q2 2026 in Review
DnB Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, buying an estimated $4.04M and bringing the position to 49,314 shares worth $30.7M. The position accounts for 0.09% of the portfolio, ranked #162.
DnB Asset Management first reported a position in REGN in Q4 2017 and has held it in 34 quarters since. The position peaked at $48.4M in Q2 2020. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- DnB Asset Management held 49,314 shares of Regeneron Pharmaceuticals worth $30.7M as of Q2 2026.
- DnB Asset Management bought 5,933 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.04M.
- Regeneron Pharmaceuticals made up 0.09% of DnB Asset Management's portfolio in Q2 2026, its #162 holding.
- DnB Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- DnB Asset Management's Regeneron Pharmaceuticals position peaked at $48.4M in Q2 2020.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.